We are excited to announce a partnership with CTMC, a joint @IncResilience & @MDAndersonNews venture, to accelerate novel cell therapy delivery. 🙌. We are looking forward to working together to enable widespread patient access to cell therapies. ➡️

@GENbio @Ori_JCFoster Hear more from Jason on the factors holding CGT back via @WSJCustom:

Bioprocessing platforms that enable flexibility and scalability are critical to meet patient demand for CGTs. With @GENbio, @Ori_JCFoster discussed how we’re partnering with best-of-breed providers and technologies to expand flexibility for developers⬇️.

🔬 @abbvie's $2.1B acquisition of @capstantx highlights continued momentum for in vivo CAR-T. By reprogramming T cells inside the body using mRNA-LNPs, the approach could sidestep manufacturing bottlenecks and make CAR-T more accessible. Read more:

Capital-intensive manufacturing with low yields continues to challenge CGT delivery. @AKAarsalan, Founder of @endpts, joined @Ori_JCFoster on the Ori Spotlight Podcast to discuss how rethinking manufacturing will allow the industry to move forward. 🎧

Attending Boston for the 4th Process Development for Cell Therapies Summit? Meet our VP of BD, Kale Feeter!. 📅 July 9–11.📍 Revere Hotel Boston Common, USA. Connect with Kale to learn more about how IRO® can help you scale the impact of your therapies ➡️

The clinical success of CGTs alone is insufficient if manufacturing and commercialization capabilities are not robust and scalable. Read our whitepaper to learn how automated and scalable manufacturing can drive commercial success and patient access➡️

Jennifer Le’s lupus diagnosis in 2016 brought ER visits, fatigue, and concerns about being able to start a family. In 2023, she joined a CAR-T trial and 6 months later, she’s back at work, and planning for the future. 🔗

Researchers at @KingsCollegeLon have engineered CAR-T cells to use fructose when glucose is scarce in solid tumors. This modification preserves anti-tumor activity which could help improve CAR-T efficacy against solid tumors. 🔗

📊 One of CGT’s biggest hurdles isn’t science. It’s economics. @endpts founder @AKAarsalan joins @Ori_JCFoster on the Ori Spotlight Podcast to talk investor sentiment, stalled assets, and why execution will define CGT’s next chapter. Listen now:.🎧

In our webinar with @CGT_Insights, our CCO @Thomas_Heathman and Senior Scientist Hamza Patel, explored how fluid dynamics can accelerate CGT development and support closed, scalable manufacturing from process development to commercial scale. Watch here:

Rehan and Parimala are South India’s longest-known CAR-T survivors. Treated at @NarayanaHealth after years of failed therapies, both are now in remission and rebuilding their life. A reminder of what’s possible when CGTs are truly accessible. 🔗

Developers need #Manufacturing solutions that evolve with the science, support rapid iteration & scale across therapy portfolios. That’s why we built IRO® – a flexible, modular platform to support development from R&D through to GMP. Read our Whitepaper➡️

🎙️ Our CEO @Ori_JCFoster is taking to the stage for @somXhealthtech's Healthtech Talks with @googlecloud, where he'll join a panel exploring the role of #tech in enabling patient impact at scale. 📆 June 30, 18:30 BST.📍London. Register your interest:

Read the full paper ➡️

How will AI, ML, and digital impact the CGTs?. Our Director, Technical Solutions, Keara Trinkle, co-authored a recently published paper in Cytotherapy examining how these technologies can enhance #Manufacturing efficiency and increase market access ⬇️.

Scientific momentum in CGTs is high, but we’re yet to see impact at scale. At @alliancerm @CGTCatapult's Workshop, @Ori_JCFoster joined the ‘Robots, Automation, and AI/ML’ panel to explore how tech can help the industry design for scale and deliver on CGT's commercial potential.

@Ori_JCFoster @WSJCustom Read the full interview:

Scientific breakthroughs mean little without scalable #Manufacturing. As @Ori_JCFoster shared with @WSJCustom, <20% of eligible patients can access CGTs because too often, commercial production is an afterthought. We need to design for scale and throughput from day 1.

In 2016, firefighter Nick Howe was diagnosed with aggressive lymphoma. When other treatments failed, he joined a CAR-T trial at @NebraskaMed. He was in remission within weeks. Now, he’s giving back, raising funds for research & patient care. 🔗

After the @US_FDA's CGT roundtable, senior leaders have acknowledged what many already know. We won’t see widespread #PatientAccess without regulatory systems that support manufacturability and commercial viability from the start.